Here's Why the Best Is Yet to Come for Exact Sciences
Millions of Americans forego getting tested for colon cancer; however, a new colon cancer test from Exact Sciences (NASDAQ: EXAS) is changing that, and as a result, patients are catching their cancer sooner. The simple test is resonating with aging baby boomers who might otherwise skip testing, and since guidelines call for testing everyone between age 50 to 74, there's still a lot of untapped market opportunity that could reward Exact Sciences' investors.
Colon cancer is easy to treat if it's caught early. However, historically low testing rates mean too many people are being diagnosed in the late stages of this disease, when it's far more difficult to fight.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Exact Sciences Stock
€41.73
-4.920%
Exact Sciences is currently one of the favorites of our community with 15 Buy predictions and no Sell predictions.
As a result the target price of 77 € shows a very positive potential of 84.52% compared to the current price of 41.73 € for Exact Sciences.
